Draft synthesis: incretin receptor agonists for metabolic dysfunction-associated steatohepatitis
Consultation on the draft synthesis of incretin receptor agonists for metabolic dysfunction-associated steatohepatitis. The anchor outcome is histological, which raises the question the consultation was principally about: whether a biopsy-defined endpoint…
§1Consultation and window
§1.1Window
- Opened
- 29 April 2026
- Closed
- 10 June 2026
- Duration
- 42 days
- Status
- Closed — the disposition is published
- Document under consultation
- Synthesis: Incretin receptor agonists for metabolic dysfunction-associated…
- Submissions received
- 12
§1.2Consultation questions
The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.
- Is the anchor outcome definition sufficiently uniform across the contributing trials for a pooled estimate to be interpretable?
- Should reader variability in histological assessment be handled as a source of imprecision or as a source of indirectness?
- Are the limitations recorded in the abstract sufficient, in particular in relation to the proportion of screened patients who did not proceed to randomisation?
§1.3How a submission is handled
- Every submission is signed. The Institute publishes no anonymous submission.
- Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
- A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
- Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
- There is no voting, no reputation score, no reply thread and no editing after receipt.
§1.4Outcome
The synthesis was amended before ratification. Reader variability is now handled and reported as imprecision with the reasoning stated, and the screening-to-randomisation proportion is reported per trial in the included-studies table.
The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.